Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 10, Pages 374
Publisher
MDPI AG
Online
2018-10-09
DOI
10.3390/cancers10100374
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment
- (2018) Takeharu Ono et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Interplay of Viral Infection, Host Cell Factors and Tumor Microenvironment in the Pathogenesis of Nasopharyngeal Carcinoma
- (2018) Shaina Huang et al. Cancers
- The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers
- (2018) Sharmila Velapasamy et al. Cancers
- Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab
- (2017) Vivek Kumar et al. Immunotherapy
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer
- (2017) Oscar Siu Hong Chan et al. ORAL ONCOLOGY
- Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma
- (2017) Marc L. Ooft et al. ORAL ONCOLOGY
- Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma
- (2017) Linfeng Zheng et al. OncoTargets and Therapy
- Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
- (2017) Xiongwen Ran et al. Drug Design Development and Therapy
- PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
- (2017) Yajuan Zhou et al. Scientific Reports
- Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
- (2017) Edwin R. Parra et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer
- (2017) Ede Birtalan et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
- (2017) Qian Zhu et al. OncoImmunology
- PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis
- (2016) Markus Hecht et al. EUROPEAN JOURNAL OF CANCER
- Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system
- (2016) Kelly A Schats et al. HISTOPATHOLOGY
- Incidence and survival of adult cancer patients in Taiwan, 2002–2012
- (2016) Chun-Ju Chiang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma
- (2016) Victor H. F. Lee et al. PLoS One
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
- (2016) Hye Ryun Kim et al. Scientific Reports
- Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
- (2015) M. Vassilakopoulou et al. CLINICAL CANCER RESEARCH
- Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
- (2015) Anne W.M. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma
- (2015) Jianwei Zhang et al. MEDICAL ONCOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof
- (2015) Tseng-Cheng Chen et al. ORAL ONCOLOGY
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
- (2015) Yueh-Min Lin et al. PLoS One
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now